Evropska unija -
slovenščina -
EMA (European Medicines Agency)
scemblix
novartis europharm limited - asciminib hydrochloride - levkemija, mielogena, kronična, bcr-abl pozitivna - antineoplastična sredstva - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
chrom cr51 edta
raztopina - [51cr]krom-edetat
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
pegasys
pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 in 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. glede na odločitev, da začne zdravljenje v pediatrični bolniki glej točki 4. 2, 4. 4 in 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 in 5. za virus hepatitisa c (hcv) genotip določene dejavnosti, glej točki 4. 2 in 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. ko se odločate za začetek zdravljenja v otroštvu, je pomembno, da preuči zaviranja rasti povzročijo kombinacija terapije. reverzibilnost zaviranja rasti je negotova. odločitev za zdravljenje mora biti vložena na podlagi primera (glej poglavje 4.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
adempas
bayer ag - riociguat - hipertenzija, pljučnica - antihipertenzivi za pljučno arterijsko hipertenzijo - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitosti je bil prikazan v pah prebivalstva, vključno z aetiologies z idiopatsko ali dedne pah ali pah, povezanih z vezivnega tkiva bolezni. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
cr51 natriumchromate
raztopina - s kromom 51cr označene celice
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
trolab patch test allergens - potasium dichromate 0,5%
suspenzija za kožni vbodni test - alergijski testi
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
patch test raztopina za epikutano testiranje - potassium dichromate 0,5%
raztopina za kožni vbodni test - alergijski testi
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
edistride
astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
forxiga
astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.